MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.1 USD | -2.63% |
|
-3.57% | +15.66% |
| 11:55am | Merck Signs Deal to Buy Eyebiotech for Up to $3 Billion, Financial Times Reports | MT |
| 03:26am | Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
126.1
USD
Average target price
141.9
USD
Spread / Average Target
+12.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.66% | 319B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +0.24% | 274B | |
| +13.14% | 238B | |
| +7.14% | 204B | |
| -6.18% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B | |
| -1.99% | 120B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Insider Sell: Merck & Co.
